S&P 500   3,367.23 (-0.38%)
DOW   29,220.49 (-0.60%)
QQQ   234.04 (-0.26%)
AAPL   317.34 (-2.34%)
FB   216.99 (+1.31%)
MSFT   186.67 (+0.71%)
AMZN   2,141.01 (+0.29%)
NVDA   288.52 (-0.44%)
BABA   219.49 (-0.06%)
MU   57.06 (-2.46%)
TSLA   849.39 (+6.17%)
AMD   56.06 (+1.34%)
T   38.23 (-0.05%)
ACB   1.55 (-1.89%)
F   8.08 (-0.25%)
NFLX   386.57 (+1.62%)
PRI   134.85 (-1.45%)
BAC   34.36 (-1.41%)
DIS   138.35 (-0.85%)
GILD   66.93 (-0.93%)
S&P 500   3,367.23 (-0.38%)
DOW   29,220.49 (-0.60%)
QQQ   234.04 (-0.26%)
AAPL   317.34 (-2.34%)
FB   216.99 (+1.31%)
MSFT   186.67 (+0.71%)
AMZN   2,141.01 (+0.29%)
NVDA   288.52 (-0.44%)
BABA   219.49 (-0.06%)
MU   57.06 (-2.46%)
TSLA   849.39 (+6.17%)
AMD   56.06 (+1.34%)
T   38.23 (-0.05%)
ACB   1.55 (-1.89%)
F   8.08 (-0.25%)
NFLX   386.57 (+1.62%)
PRI   134.85 (-1.45%)
BAC   34.36 (-1.41%)
DIS   138.35 (-0.85%)
GILD   66.93 (-0.93%)
S&P 500   3,367.23 (-0.38%)
DOW   29,220.49 (-0.60%)
QQQ   234.04 (-0.26%)
AAPL   317.34 (-2.34%)
FB   216.99 (+1.31%)
MSFT   186.67 (+0.71%)
AMZN   2,141.01 (+0.29%)
NVDA   288.52 (-0.44%)
BABA   219.49 (-0.06%)
MU   57.06 (-2.46%)
TSLA   849.39 (+6.17%)
AMD   56.06 (+1.34%)
T   38.23 (-0.05%)
ACB   1.55 (-1.89%)
F   8.08 (-0.25%)
NFLX   386.57 (+1.62%)
PRI   134.85 (-1.45%)
BAC   34.36 (-1.41%)
DIS   138.35 (-0.85%)
GILD   66.93 (-0.93%)
S&P 500   3,367.23 (-0.38%)
DOW   29,220.49 (-0.60%)
QQQ   234.04 (-0.26%)
AAPL   317.34 (-2.34%)
FB   216.99 (+1.31%)
MSFT   186.67 (+0.71%)
AMZN   2,141.01 (+0.29%)
NVDA   288.52 (-0.44%)
BABA   219.49 (-0.06%)
MU   57.06 (-2.46%)
TSLA   849.39 (+6.17%)
AMD   56.06 (+1.34%)
T   38.23 (-0.05%)
ACB   1.55 (-1.89%)
F   8.08 (-0.25%)
NFLX   386.57 (+1.62%)
PRI   134.85 (-1.45%)
BAC   34.36 (-1.41%)
DIS   138.35 (-0.85%)
GILD   66.93 (-0.93%)
Log in

OTCMKTS:MRNA - Marina Biotech Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$18.75
-0.25 (-1.32 %)
(As of 02/18/2020 10:47 AM ET)
Today's Range
$18.71
Now: $18.75
$19.35
50-Day Range
$12.17
MA: $14.00
$15.31
52-Week Range
$11.54
Now: $18.75
$29.79
Volume1.01 million shs
Average Volume1.15 million shs
Market Capitalization$6.17 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Marina Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company is headquartered in City of Industry, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MRNA
Previous SymbolOTCMKTS:MRNAD
CUSIPN/A
Phone626-964-5788

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$6.17 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.


Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions

What is Marina Biotech's stock symbol?

Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."

How were Marina Biotech's earnings last quarter?

Marina Biotech, Inc. (OTCMKTS:MRNA) released its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.37) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.06. The biotechnology company had revenue of $17.05 million for the quarter, compared to analysts' expectations of $17.64 million. The firm's quarterly revenue was down 59.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.24) EPS. View Marina Biotech's Earnings History.

What price target have analysts set for MRNA?

10 analysts have issued 12-month target prices for Marina Biotech's stock. Their forecasts range from $20.00 to $40.00. On average, they expect Marina Biotech's stock price to reach $26.40 in the next twelve months. This suggests a possible upside of 39.2% from the stock's current price. View Analyst Price Targets for Marina Biotech.

What is the consensus analysts' recommendation for Marina Biotech?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marina Biotech in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marina Biotech.

Has Marina Biotech been receiving favorable news coverage?

News coverage about MRNA stock has been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Marina Biotech earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Marina Biotech.

Who are some of Marina Biotech's key competitors?

What other stocks do shareholders of Marina Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marina Biotech investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), NVIDIA (NVDA), Twilio (TWLO), Micron Technology (MU), AMC Entertainment (AMC), First Data (FDC), Associated British Foods (ABF) and Chaarat Gold (CGH).

Who are Marina Biotech's key executives?

Marina Biotech's management team includes the folowing people:
  • Mr. Erik Emerson, Chief Commercial Officer & Director (Age 47)
  • Mr. Robert C. Moscato Jr., CEO & Director (Age 42)
  • Mr. Amit Shah, Chief Financial Officer (Age 52)
  • Mr. Mihir Munsif, Chief Operating Officer (Age 55)
  • Dr. Larn Hwang, Chief Scientific Officer (Age 55)

Who are Marina Biotech's major shareholders?

Marina Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Moody Lynn & Lieberson LLC (0.02%), Moloney Securities Asset Management LLC (0.01%), Teza Capital Management LLC (0.01%), Sowell Financial Services LLC (0.00%) and IFP Advisors Inc (0.00%). Company insiders that own Marina Biotech stock include Edwin M Kania Jr, Lorence H Kim, Peter Barton Hutt, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and Ventures Fund Iv Gene Flagship. View Institutional Ownership Trends for Marina Biotech.

Which major investors are selling Marina Biotech stock?

MRNA stock was sold by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC. Company insiders that have sold Marina Biotech company stock in the last year include Edwin M Kania Jr, Lorence H Kim, Peter Barton Hutt, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and Ventures Fund Iv Gene Flagship. View Insider Buying and Selling for Marina Biotech.

Which major investors are buying Marina Biotech stock?

MRNA stock was purchased by a variety of institutional investors in the last quarter, including Moody Lynn & Lieberson LLC, Teza Capital Management LLC, Sowell Financial Services LLC and IFP Advisors Inc. View Insider Buying and Selling for Marina Biotech.

What is Marina Biotech's stock price today?

One share of MRNA stock can currently be purchased for approximately $18.96.

How big of a company is Marina Biotech?

Marina Biotech has a market capitalization of $6.24 billion. View Additional Information About Marina Biotech.

What is Marina Biotech's official website?

The official website for Marina Biotech is http://www.marinabio.com/.

How can I contact Marina Biotech?

Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected]


MarketBeat Community Rating for Marina Biotech (OTCMKTS MRNA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel